Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Hyaluronidase (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms HALO-301
- Sponsors Halozyme Therapeutics
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium
- 05 Dec 2019 This trial has been completed in Belhium and france, according to European Clinical Trials Database.
- 02 Dec 2019 Status changed from active, no longer recruiting to discontinued.